Petrus Trust Company LTA Acquires 5,173 Shares of Illumina, Inc. $ILMN

Key Points

• Petrus Trust Company LTA increased its holdings in Illumina, Inc. by 209%, now owning 7,648 shares valued at $607,000, according to its recent SEC filing.
• Several other institutional investors also boosted their positions in Illumina during the 1st quarter, with a significant ownership of 89.42% by hedge funds and other institutions.
• Illumina's stock has a consensus rating of "Hold" with an average price target of $123.06, despite varying opinions from multiple analysts on its investment potential.

Petrus Trust Company LTA boosted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 209.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,648 shares of the life sciences company's stock after acquiring an additional 5,173 shares during the quarter. Petrus Trust Company LTA's holdings in Illumina were worth $607,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Moors & Cabot Inc. lifted its holdings in shares of Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after purchasing an additional 145 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Illumina by 3.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock worth $445,000 after purchasing an additional 164 shares during the period. Nissay Asset Management Corp Japan ADV lifted its holdings in shares of Illumina by 0.9% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company's stock worth $1,774,000 after purchasing an additional 207 shares during the period. Probity Advisors Inc. lifted its holdings in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock valued at $274,000 after buying an additional 224 shares during the period. Finally, Xponance Inc. lifted its holdings in Illumina by 1.0% in the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock valued at $2,123,000 after buying an additional 264 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 4.0%

ILMN traded up $3.82 during midday trading on Thursday, hitting $99.31. The company had a trading volume of 740,627 shares, compared to its average volume of 2,251,541. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $15.26 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 2.21 and a beta of 1.43. The stock's 50 day moving average price is $99.59 and its 200 day moving average price is $88.53.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm posted $0.36 earnings per share. The business's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Evercore ISI boosted their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a report on Monday, August 4th. Barclays boosted their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a report on Friday, August 1st. Finally, Daiwa Capital Markets lowered shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price on the stock. in a report on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $123.06.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.